ClinicalTrials.Veeva

Menu

Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy

C

Chiba University

Status and phase

Unknown
Phase 4

Conditions

Pancreatic Tumor
Bile Duct Tumor

Treatments

Dietary Supplement: Oral IMPACT

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of this study is to investigate whether perioperative immunonutrition has additional effects on cell-mediated immunity in patients undergoing pancreaticoduodenectomy.

Full description

The investigators reported that perioperative immunonutrition had no additional effects compared with preoperative immunonutrition in patients underwent colorectal surgery (Braga M, Gianotti L, Vignali A, Carlo VD. Preoperative oral arginine and n-3 fatty acid supplementation improves the immunometabolic host response and outcome after colorectal resection for cancer. Surgery. 2002; 132:805-14, PMID: 12464864). Object of this study is to investigate the additional effects of perioperative immunonutrition on cell-mediated immunity and incidence of infectious complication after pancreaticoduodenectomy.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients undergoing pancreaticoduodenectomy

Exclusion criteria

  • age younger than 18 years old
  • ongoing infection
  • gastrointestinal obstruction
  • respiratory dysfunction
  • cardiac dysfunction
  • hepatic dysfunction
  • renal failure
  • history of recent immunosuppressive or immunological disease
  • preoperative evidence of widespread metastatic disease

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

Perioperative
Active Comparator group
Description:
Oral IMPACT (1 L/day) for 5 days before surgery and by enteral feeding after surgery
Treatment:
Dietary Supplement: Oral IMPACT
Preoperative
Active Comparator group
Description:
Oral IMPACT 1000ml/day for 5 days (1 L/day) before surgery
Treatment:
Dietary Supplement: Oral IMPACT

Trial contacts and locations

1

Loading...

Central trial contact

Daisuke Suzuki, MD; Katsunori Furukawa, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems